کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6183650 1254111 2013 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer
ترجمه فارسی عنوان
یک مطالعه آینده نگر ارزیابی ارتباط بالینی یک آزمایش شیمیایی برای درمان بیماران مبتلا به سرطان تخمدان دائمی یا مکرر
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
چکیده انگلیسی


• A prospective clinical trial examines the ability of a chemoresponse assay to improve clinical outcomes in recurrent ovarian cancer.
• Patients treated with an assay-sensitive treatment had significantly improved clinical outcomes over those treated with a non-sensitive treatment.
• Although only 25% of patients were empirically treated with a sensitive treatment, over 50% had at least one sensitive result.

ObjectiveUse of in vitro chemoresponse assays for informing effective treatment selection is a compelling clinical question and a topic of debate among oncologists. A prospective study was conducted evaluating the use of a chemoresponse assay in recurrent ovarian cancer patients.MethodsWomen with persistent or recurrent ovarian cancer were enrolled under an IRB-approved protocol, and fresh tissue samples were collected for chemoresponse testing. Patients were treated with one of 15 protocol-designated treatments empirically selected by the oncologist, blinded to the assay results. Each treatment was classified by the assay as: sensitive (S), intermediate (I), or resistant (R). Patients were prospectively monitored for progression-free survival (PFS) and overall survival (OS). Associations of assay response for the physician-selected treatment with PFS and OS were analyzed.ResultsA total of 262 evaluable patients were enrolled. Patients treated with an assay-sensitive regimen demonstrated significantly improved PFS and OS while there was no difference in clinical outcomes between I and R groups. Median PFS was 8.8 months for S vs. 5.9 months for I + R (hazard ratio [HR] = 0.67, p = 0.009). The association with assay response was consistent in both platinum-sensitive and platinum-resistant tumors (HR: 0.71 vs. 0.66) and was independent of other covariates in multivariate analysis (HR = 0.66, p = 0.020). A statistically significant14-month improvement in mean OS (37.5 months for S vs. 23.9 months for I + R, HR = 0.61, p = 0.010) was demonstrated.ConclusionsThis prospective study demonstrated improved PFS and OS for patients with either platinum-sensitive or platinum-resistant recurrent ovarian cancer treated with assay-sensitive agents.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 131, Issue 2, November 2013, Pages 362–367